U.S. Interleukin Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: U.S. Interleukin Market (interleukin-targeting biologics, drug substance and finished products)
- ✓Market Size 2024: US$48 billion
- ✓Market Size 2032: US$82 billion
- ✓CAGR: 7.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Secure Onshore Fill-Finish Capacity: Procurement and investment teams should lock multi-year supply agreements for IL-23 and IL-17 drug substance with US-based fill-finish capacity before the fourth quarter of 2026, because Section 232 pharmaceutical tariff exposure remains unresolved and onshoring commitments are tightening.
The United States' Role in the Global Interleukin Supply Chain
The United States is the world's largest consumer of interleukin-targeting biologics, yet its supply chain role is weighted toward finishing and bulk manufacturing rather than raw material production. Domestic drug substance output is concentrated at Amgen's Juncos, Puerto Rico and Holly Springs, North Carolina operations and Fujifilm Diosynth's Holly Springs campus. Finished biologics from Ireland, Switzerland and Germany account for a large share of imports, with Ireland supplying substantial immunology volumes into US distribution.
Import dependency is highest for upstream bioprocess inputs. Single-use bioreactor components, cell culture media and chromatography resins draw heavily on German and Singaporean suppliers, while peptide intermediates arrive from China and India. Net exports flow in the opposite direction for finished monoclonal antibodies bound for Canada and Japan. The result is a country that captures high value at the end of the chain but imports much of its manufacturing foundation.
Growth Drivers for U.S. Interleukin Production and Trade
Onshoring commitments are the most material driver of production capacity. Eli Lilly, Johnson & Johnson and AbbVie have announced multibillion-dollar US manufacturing investments since 2025, adding bioreactor capacity that reduces reliance on Irish and Swiss fill-finish sites. This shifts the import mix from finished vials toward bulk drug substance, which carries lower tariff exposure and raises domestic value capture. Expansion also lifts demand for domestic single-use equipment and cold-chain freight.
Pipeline expansion is the second driver. Next-generation IL-23, IL-17 and IL-4/13 agents are moving into pediatric and additional indications, sustaining volume growth through specialty distribution networks. Biosimilar competition for IL-12/23 volumes pushes originators toward lower manufacturing cost structures, increasing contract demand for domestic CDMO capacity in North Carolina and New Jersey. Import substitution follows as companies bring peptide and reagent sourcing onshore.
Supply Chain Risks and Trade Barriers in U.S. Interleukin Supply
Bioprocess inputs remain concentrated among a small number of suppliers. Single-use bioreactor film, cell culture media components and specialized chromatography resins are sourced largely from Germany and Singapore, creating single-point failure risk. Any disruption to Sartorius or Merck KGaA shipments would delay US drug substance release by months, because qualification of alternative materials requires lengthy regulatory filings and validation runs.
Trade policy creates the second exposure. Section 232 pharmaceutical tariffs and reciprocal tariff frameworks with the EU, Japan and Switzerland introduce uncertainty for finished biologic imports, particularly for products invoiced in euros and Swiss francs. Transatlantic air cargo lanes face capacity constraints during peak seasons, and temperature-controlled freight costs rise when lanes tighten. Currency volatility compresses margins for importers whose revenues are denominated in dollars but whose contracts are priced in foreign currency.
Trade and Investment Opportunities in U.S. Interleukin Manufacturing
Bulk drug substance capacity for IL-23 and IL-17 antibodies is underbuilt relative to demand, creating an opening for contract manufacturers. Lonza's Portsmouth, New Hampshire site and Fujifilm's Holly Springs campus are natural candidates for expansion contracts with originators. Investors should target mid-scale single-use facilities in North Carolina and New Jersey, where skilled biopharma labor and FDA inspection proximity align with customer demand.
Import substitution for peptide intermediates and cytokine reagents is commercially viable. Domestic producers of GMP-grade interleukin proteins could serve US biotech clients currently sourcing from China and India. Logistics hub development at Memphis, Tennessee, which hosts major air cargo operations, could support temperature-controlled biologics distribution to Canada and Latin America, linking domestic manufacturing to regional export flows.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | US$48 billion |
| Market Size 2032 | US$82 billion |
| Growth Rate (CAGR) | 7.2% |
| Most Critical Decision Factor | Secure onshore bulk drug substance capacity ahead of tariff changes |
| Largest Region | Northeast and Mid-Atlantic corridor |
| Competitive Structure | Oligopolistic, led by five multinational originators |
Leading Market Participants
- AbbVie
- Johnson & Johnson
- Novartis
- Eli Lilly
- Regeneron Pharmaceuticals
- Sanofi
- Amgen
- Genentech
- UCB
- GSK
Regulatory and Trade Policy Affecting U.S. Interleukin Imports and Exports
The US trade framework for biologics combines bilateral tariff arrangements with sector-specific measures. The 2025 US-EU framework set a 15% ceiling on most European goods, and comparable arrangements cover Japan and Switzerland. USMCA governs trade with Canada and Mexico but carries limited direct relevance to finished biologics. The Section 232 pharmaceutical investigation remains the most consequential open policy lever for interleukin imports.
Investment and pricing policy shape the market equally. Medicare drug price negotiation selected Stelara for initial pricing, accelerating biosimilar substitution in IL-12/23 volumes. FDA cGMP inspection requirements and biologics license approvals govern every import and domestic production site, while foreign trade zones allow bonded storage of drug substance awaiting tariff clarity. Proposed BIOSECURE restrictions on certain foreign biotech suppliers add further scrutiny to supplier selection.
U.S. Interleukin Supply Chain Outlook to 2032
The supply chain will shift from importing finished interleukin products toward domestic bulk drug substance production through 2032. Puerto Rico and North Carolina will anchor this expansion, while Ireland and Switzerland retain specialized fill-finish roles for European-licensed products. Freight flows will reorient toward domestic distribution hubs, reducing exposure to transatlantic lane disruption.
Technology will alter comparative advantage. Continuous bioprocessing and AI-driven process analytics reduce batch cycle times, favoring facilities that can adopt these systems quickly. Bispecific antibodies and next-generation interleukin modulators will require new upstream inputs, so suppliers of specialized media and resins that localize production in the United States will capture disproportionate share of incremental demand.
Frequently Asked Questions
Market Segmentation
- IL-23
- IL-17
- IL-4 and IL-13
- IL-6
- IL-12 and IL-23
- Plaque Psoriasis
- Atopic Dermatitis
- Rheumatoid Arthritis
- Severe Asthma
- Inflammatory Bowel Disease
- Hospital Pharmacies
- Specialty Pharmacies
- Retail Pharmacies
- Mail-Order Pharmacies
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.